Skip to content

Skip to secondary menu

Jehovah’s Witnesses


Beta Thalassemia (Pediatrics)

Beta Thalassemia Intermedia and Minor—Pharmacological Induction of Fetal Hemoglobin Synthesis

Fetal hemoglobin inducers from the natural world: a novel approach for identification of drugs for the treatment of {beta}-thalassemia and sickle-cell anemia.

Bianchi N, Zuccato C, Lampronti I, Borgatti M, Gambari R.

Source‎: Evid Based Complement Alternat Med 2009;6(2):141-51.

Indexed‎: PubMed 18955291

DOI‎: 10.1093/ecam/nem139

Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E-β-thalassemia): a single center study from eastern India.

Bohara VV, Ray S, Chakrabarti P, Ray SS, Nath UK, Chaudhuri U.

Source‎: Hemoglobin. 2014;38(1):44-8.

Indexed‎: PubMed 24144212

DOI‎: 10.3109/03630269.2013.845844

Treatment of beta-thalassemia patients with recombinant human erythropoietin: effect on transfusion requirements and soluble adhesion molecules.

Chaidos A, Makis A, Hatzimichael E, Tsiara S, Gouva M, Tzouvara E, Bourantas KL.

Source‎: Acta Haematol 2004;111(4):189-95.

Indexed‎: PubMed 15153710

Hydroxyurea in thalassemia intermedia--a promising therapy.

Dixit A, Chatterjee TC, Mishra P, Choudhry DR, Mahapatra M, Tyagi S, Kabra M, Saxena R, Choudhry VP.

Source‎: Ann Hematol 2005;84(7):441-6.

Indexed‎: PubMed 15838670

Therapeutic superiority and safety of combined hydroxyurea with recombinant human erythropoietin over hydroxyurea in young β-thalassemia intermedia patients.

Elalfy MS, Adly AA, Ismail EA, Elhenawy YI, Elghamry IR.

Source‎: Eur J Haematol 2013;91(6):522-33.

Indexed‎: PubMed 23927461

DOI‎: 10.1111/ejh.12182

A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia.

Fucharoen S, Inati A, Siritanaratku N, Thein SL, Wargin WC, Koussa S, Taher A, Chaneim N, Boosalis M, Berenson R, Perrine SP.

Source‎: Br J Haematol 2013;161(4):587-93.

Indexed‎: PubMed 23530969

DOI‎: 10.1111/bjh.12304

Effect of hydroxyurea on the transfusion requirements in patients with severe HbE-beta-thalassaemia: a genotypic and phenotypic study.

Italia KY, Jijina FF, Merchant R, Panjwani S, Nadkarni AH, Sawant PM, Nair SB, Ghosh K, Colah RB.

Source‎: J Clin Pathol 2010;63(2):147-50.

Indexed‎: PubMed 20154037

DOI‎: 10.1136/jcp.2009.070391

Echocardiographic finding in beta-thalassemia intermedia and major: absence of pulmonary hypertension following hydroxyurea treatment in beta-thalassemia intermedia.

Karimi M, Borzouee M, Mehrabani A, Cohan N.

Source‎: Eur J Haematol 2009;82(3):213-8.

Indexed‎: PubMed 19077048

DOI‎: 10.1111/j.1600-0609.2008.01192.x

Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran.

Karimi M, Darzi H, Yavarian M.

Source‎: J Pediatr Hematol Oncol 2005;27(7):380-5.

Indexed‎: PubMed 16012328

Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia.

Karimi M, Mohammadi F, Behmanesh F, Samani SM, Borzouee M, Amoozgar H, Haghpanah S.

Source‎: Eur J Haematol 2010;84(1):52-8.

Indexed‎: PubMed 19799627

DOI‎: 10.1111/j.1600-0609.2009.01356.x

Single and combination drug therapy for fetal hemoglobin augmentation in hemoglobin E-beta 0-thalassemia: Considerations for treatment.

Singer ST, Kuypers FA, Olivieri NF, Weatherall DJ, Mignacca R, Coates TD, Davies S, Sweeters N, Vichinsky EP.

Source‎: Ann N Y Acad Sci 2005;1054:250-6.

Indexed‎: PubMed 16339672

Darbepoetin alfa for the treatment of anaemia in alpha- or beta- thalassaemia intermedia syndromes.

Singer ST, Vichinsky EP, Sweeters N, Rachmilewitz E.

Source‎: Br J Haematol 2011;154(2):281-4.

Indexed‎: PubMed 21496003

DOI‎: 10.1111/j.1365-2141.2011.08617.x

Butyric acid: what is the future for this old substance?

Sossai P.

Source‎: Swiss Med Wkly 2012;142:w13596.

Indexed‎: PubMed 22674349

DOI‎: 10.4414/smw.2012.13596

The emerging role of fetal hemoglobin induction in non-transfusion-dependent thalassemia.

Thein SL.

Source‎: Blood Rev 2012;26 Suppl 1:S35-9.

Indexed‎: PubMed 22631042

DOI‎: 10.1016/S0268-960X(12)70011-5

The medical section of is designed as an informational resource primarily for use by clinicians and other health-care professionals. It provides neither medical advice nor treatment recommendations and does not substitute for an appropriately qualified health-care provider. The clinical literature cited is not published by Jehovah’s Witnesses, but it outlines transfusion-alternative strategies that might be considered. It is the responsibility of each qualified health-care provider to maintain awareness of new information, discuss options for care, and assist patients in making choices in accord with their medical condition, wishes, values, and beliefs. Not all listed strategies are appropriate or acceptable to all patients.

Patients: Always seek the advice of your doctor or other qualified health-care provider regarding medical conditions or treatments. Check with a doctor if you suspect you are ill.

The use of this website is governed by its terms of use.